Chris Hibberd

Chris Hibberd has more than 20 years of industry experience, leading global organizations that deliver high medical value products. Chris serves as CEO and Executive Chairman of Nucleix, a liquid biopsy company revolutionizing cancer treatment by detecting the disease earlier. Prior to Nucleix, he was CEO and Co-Founder of Astute Medical, where he led the organization and securing of funding to support a product pipeline that included the launch of NephroCheck®, the first FDA cleared diagnostic for acute kidney injury risk, until its acquisition by bioMérieux. Mr. Hibberd previously served as Senior Vice President of Corporate Development at Biosite and earlier in his career, Chris was a manager at The Boston Consulting Group and a development engineer at Albright & Wilson Americas. He has an MBA from the University of Western Ontario and a B.A.Sc. in chemical engineering from the University of Toronto.